Literature DB >> 1835593

Reaction kinetics of cisplatin and its monoaquated species with the modulating agents (di)mesna and thiosulphate.

O R Leeuwenkamp1, J P Neijt, W J van der Vijgh, H M Pinedo.   

Abstract

The reactive and rapidly excreted thiol mesna (2-mercaptoethane-sulphonate sodium) has the potential to reduce the dose-limiting nephrotoxicity of cisplatin by chemical neutralisation of the latter in the kidney. The reaction kinetics of cisplatin with mesna and its disulphide, dimesna, was studied at 37 degrees C in unbuffered 0.15 mol/l NaCl (pH 5.3) and in 0.15 mol/l NaCl buffered with 0.02 mol/l Hepes (pH 7.4). The reaction mixtures were analysed for intact cisplatin. In the presence of mesna or dimesna 0.5 mol/l as anticipated in urine for conditions of renal protection, the half-life (t1/2) of 0.2 mmol/l cisplatin was less than 6 min. t1/2 of 151 and 629 min were found in the presence of mesna and dimesna concentrations of 5 mmol/l and 3 mmol/l, respectively, anticipated in plasma under conditions of renal protection. Cis-diamminemonoaquamonochloroplatinum(II) 0.2 mmol/l reacted rapidly with 50 mmol thiosulphate and 0.5 mol/l (di)mesna (t1/2 less than or equal to 1 min). This platinum species also reacted rapidly with 2.6 mmol/l thiosulphate (t1/2 less than 1 min), a concentration reached in plasma for conditions under renal protection. Reaction of the monoaquated form of cisplatin proceeded slowly in the presence of dimesna or mesna concentrations (less than 5 mmol/l), as anticipated in plasma under renal protecting conditions. It is hypothesised that renal protection by the strong nucleophiles, thiosulphate, mesna and dimesna occurs rather by neutralisation of the aquated species in the lumen of the renal tubulus than by neutralisation of intact cisplatin, and that neutralisation of these species in plasma contributes significantly to the protecting effect.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1835593     DOI: 10.1016/0277-5379(91)90090-z

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  6 in total

1.  Mesna (2-mercaptoethane sodium sulfonate) functions as a regulator of myeloperoxidase.

Authors:  Roohi Jeelani; Seyedehameneh Jahanbakhsh; Hamid-Reza Kohan-Ghadr; Mili Thakur; Sana Khan; Sarah R Aldhaheri; Zhe Yang; Peter Andreana; Robert Morris; Husam M Abu-Soud
Journal:  Free Radic Biol Med       Date:  2017-05-25       Impact factor: 7.376

Review 2.  Pharmacokinetic drug interactions with anticancer drugs.

Authors:  P M Loadman; M C Bibby
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

3.  Influence of mesna on the pharmacokinetics of cisplatin and carboplatin in pediatric cancer patients.

Authors:  Shahbal B Kangarloo; Suman B Gangopadhyay; Rachel M Syme; Johannes E A Wolff; Stefan Glück
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

4.  Phase I and pharmacologic study of BNP7787, a novel chemoprotector in patients with advanced non-small cell lung cancer.

Authors:  Noriyuki Masuda; Shunichi Negoro; Frederick Hausheer; Kazuhiko Nakagawa; Kaoru Matsui; Shinzoh Kudoh; Koji Takeda; Nobuyuki Yamamoto; Naruo Yoshimura; Yasuo Ohashi; Masahiro Fukuoka
Journal:  Cancer Chemother Pharmacol       Date:  2010-05-15       Impact factor: 3.333

5.  Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule.

Authors:  E Boven; M Westerman; C J van Groeningen; M Verschraagen; R Ruijter; I Zegers; W J F van der Vijgh; G Giaccone
Journal:  Br J Cancer       Date:  2005-05-09       Impact factor: 7.640

6.  Pharmacokinetic behaviour of the chemoprotectants BNP7787 and mesna after an i.v. bolus injection in rats.

Authors:  M Verschraagen; E Boven; E Torun; C A M Erkelens; F H Hausheer; W J F van der Vijgh
Journal:  Br J Cancer       Date:  2004-04-19       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.